BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 20, 2025
Home » Authors » Katie Pfaff

Articles by Katie Pfaff

Panel discusses future changes in health care

Sep. 26, 2017
By Katie Pfaff

Volitionrx RUO kits hit market for pharma companion dx

Sep. 25, 2017
By Katie Pfaff

Abiomed wins PMA for right heart failure device

Sep. 22, 2017
By Katie Pfaff
Abiomed Inc. has added to its heart support portfolio with a PMA approval for the Impella RP heart pump for temporary right ventricular support after left ventricular assist device (LVAD) implantation, heart attack, surgery or transplant. The device was previously granted the FDA's humanitarian device exemption.
Read More

Mevion proton therapy reaches 510(k) premarket notification

Sep. 20, 2017
By Katie Pfaff

Studies: Memed tackles diagnosing infection as bacterial or viral

Sep. 19, 2017
By Katie Pfaff

Is open source the future of pharma and med tech, or an anomaly?

Sep. 18, 2017
By Katie Pfaff
Technology seems to leap ahead at an astounding pace and is disruptive for many businesses, but is achingly slow for patients who await disease detection and treatments. A recent TED Radio Hour, “Fighting Cancer,” included speakers who addressed their approaches to speeding the move toward more precise and faster-acting cancer diagnostics and targeted therapies. James Bradner of Dana Farber Cancer Institute, and president of Novartis Institutes for Biomedical Research, was part of a research team which shared the molecule they discovered to treat a rare form of cancer publicly. The normal steps after research of protecting the information and developing...
Read More

Seed funding to propel Prellis toward 3-D organ printing that includes built in microvasculature

Sep. 18, 2017
By Katie Pfaff
Prellis Biologics has won $1.8 million in seed funding for its 3-D printed tissue technology aimed to create human organs for transplant. The firm intends to surpass the obstacle that has so far delayed organ manufacture by building microvasculature into the tissue.
Read More

Nativis expands recurrent glioblastoma multiforme study to more patients

Sep. 15, 2017
By Katie Pfaff

Zimmer Biomet launches Persona partial knee system

Sep. 14, 2017
By Katie Pfaff

Cooper Companies buys Teva IUD for $1.1B in cash

Sep. 13, 2017
By Katie Pfaff
Coopersurgical has agreed to buy Teva Pharmaceuticals Industries Ltd.'s Paragard intrauterine device (IUD) for $1.1 billion in cash and is expected to close the deal late this year. The acquisition includes Teva's exclusive Paragard manufacturing facility in Buffalo, N.Y., and marks continued effort to divest Teva's global women's health business, according to the company.
Read More
Previous 1 2 … 12 13 14 15 16 17 18 19 20 … 23 24 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing